7 healthcare AI companies make the Forbes top 50

Dave Pearson | | Health Exec |
Artificial Intelligence

Forbes has selected 50 AI startups from 400 or so entrants as America’s “most promising” AI companies. Seven of the 50 are in healthcare.

The seven and their subcategories within healthcare are:

  • Atomwise (drug discovery)
  • Biofourmis (patient monitoring via wearables)  
  • Genesis Therapeutics (drug discovery)
  • Karius (blood-pathogen analysis)
  • Recursion (drug discovery)  
  • twoXAR (drug discovery)  
  • Viz.ai (imaging interpretation)
AI 50: America’s Most Promising Artificial Intelligence Companies

Forbes says its scoring system combines algorithmic quantification with human judgment.

One of the human judges, Caltech professor and Nvidia researcher Anima Anandkumar, says the whittling process looked past the technological marvels in order to “focus on the problem and impact side.”

Read the rest and see the full list:

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.